
CDSCO Panel Clears AstraZeneca's Datopotamab for Breast Cancer, Seeks Phase IV Trial
The approval came after deliberations during the SEC Oncology meeting held on 8th July 2025. AstraZeneca submitted its proposal seeking approval to import and market Datopotamab Deruxtecan 100 mg for the treatment of adult patients with unresectable or …